RxDoctor Payments Data

Nathan Walker, MD

Internal Medicine · Champaign, ILNPI 1629087325

Payments from drug & device makers

$955in general payments, 2019–2025

Across 70 payments — averaging $13.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$159
  • Astellas Pharma US Inc$116
  • AstraZeneca$111
  • Pfizer$110
  • Abbott$94
  • Novo Nordisk$93
  • plus $272 from 9 others

What the payments were for

  • Food & beverage$76981%
  • Education$18519%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$955 in reported general payments places this provider in the 75th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$336,007
Medicare patients
551
Services billed
15,566

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban219$254,959
JardianceEmpagliflozin187$227,509
OzempicSemaglutide157$226,562
MounjaroTirzepatide91$117,691
XareltoRivaroxaban94$111,145
Trelegy ElliptaFluticasone/Umeclidin/Vilanter117$90,468
RybelsusSemaglutide36$51,131
EntrestoSacubitril/Valsartan33$41,585
TrulicityDulaglutide29$38,933
Synjardy XrEmpagliflozin/Metformin Hcl17$30,165
IsentressRaltegravir Potassium13$29,894
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$25,269
LinzessLinaclotide28$23,897
Breztri AerosphereBudesonide/Glycopyr/Formoterol33$22,924
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr39$22,381

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$93$277,692193 claims
PfizerEliquis$110$254,959219 claims
Lilly USA, LLCMounjaro, Trulicity$159$156,624120 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$46$130,468186 claims
Johnson & JohnsonXarelto$15$111,14594 claims
NovartisEntresto$25$41,58533 claims
AstraZenecaBreztri Aerosphere, Symbicort$111$31,19959 claims
AbbVieLinzess$46$23,89728 claims
Astellas Pharma US IncMyrbetriq$116$16,47118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Champaign

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →